Benzinga's Top Upgrades, Downgrades For May 2, 2018

Top Upgrades

• Mizuho upgraded Ironwood Pharmaceuticals, Inc. IRWD from Neutral to Buy. Ironwood Pharmaceuticals shares rose 2.09 percent to $19.08 in pre-market trading.
• Wedbush upgraded TCF Financial Corporation TCF from Underperform to Neutral. TCF Financial shares rose 1.33 percent to close at $25.16 on Tuesday.
• Raymond James upgraded United States Cellular Corporation USM from Market Perform to Outperform. United States Cellular shares fell 14.03 percent to close at $34.02 on Monday.
• Analysts at Deutsche Bank upgraded Juniper Networks, Inc. JNPR from Sell to Hold. Juniper shares rose 6.87 percent to $26.45 in pre-market trading.
• Bank of America upgraded Vulcan Materials Company VMC from Neutral to Buy. Vulcan Materials shares rose 0.07 percent to close at $111.77 on Tuesday.
• DA Davidson upgraded Domtar Corporation UFS from Underperform to Neutral. Domtar shares rose 2.67 percent to close at $45.07 on Monday.
• Bank of America upgraded Eaton Vance Corp. EV from Neutral to Buy. Eaton Vance shares fell 1.08 percent to close at $53.80 on Monday.
• CIBC upgraded Freeport-McMoRan Inc. FCX from Neutral to Outperformer. Freeport-McMoRan shares rose 2.08 percent to $15.23 in pre-market trading.
• Monness Crespi Hardt upgraded Archer-Daniels-Midland Company ADM from Sell to Neutral. Archer-Daniels Midland shares rose 0.47 percent to $45.24 in pre-market trading.
• Goldman Sachs upgraded Shutterfly, Inc. SFLY from Sell to Neutral. Shutterfly shares rose 10.97 percent to $90.50 in pre-market trading.

Top Downgrades

• Oppenheimer downgraded Snap Inc. SNAP from Outperform to Perform. Snap shares fell 19.84 percent to $11.33 in pre-market trading.
• Loop Capital downgraded Ulta Beauty, Inc. ULTA from Buy to Hold. Ulta Beauty shares fell 0.65 percent to $249.00 in pre-market trading.
• Buckingham downgraded Cummins Inc. CMI from Buy to Neutral. Cummins shares fell 2.79 percent to $149.00 in pre-market trading.
• Longbow Research downgraded Denny's Corporation DENN from Buy to Neutral. Denny's shares dropped 3.65 percent to $16.65 in pre-market trading.
• UBS downgraded PACCAR Inc PCAR from Buy to Neutral. PACCAR shares fell 0.14 percent to close at $63.58 on Monday.
• Craig-Hallum downgraded Seagate Technology plc STX from Buy to Hold. Seagate shares fell 2.23 percent to $53.00 in pre-market trading.
• Analysts at SunTrust Robinson Humphrey downgraded KLX Inc. KLXI from Buy to Hold. KLX shares fell 8.6 percent to close at $62.25 on Tuesday.
• BMO Capital downgraded NuVasive, Inc. NUVA from Outperform to Market Perform. NuVasive shares fell 3.82 percent to $51.11 in pre-market trading.
• Argus downgraded Hershey Company HSY from Buy to Hold. Hershey shares fell 0.67 percent to close at $91.32 on Monday.
• Bank of America downgraded The Scotts Miracle Gro SMG from Buy to Underperform. Intevac shares fell 22.90 percent to $5.05 in pre-market trading.

Top Initiations

• Analysts at B. Riley FBR initiated coverage on Mallinckrodt Public Limited Company MNK with a Neutral rating. The price target for Mallinckrodt is set to $15. Mallinckrodt shares closed at $13.10 on Tuesday.
• Analysts at Jefferies initiated coverage on Sierra Metals Inc. SMTS with a Hold rating. Sierra Metals shares closed at $2.76 on Tuesday.
• H.C. Wainwright initiated coverage on ChemoCentryx, Inc. CCXI with a Buy rating. The price target for ChemoCentryx is set to $20. ChemoCentryx shares closed at $11.00 on Tuesday.
• UBS initiated coverage on Fortis Inc. FTS with a Buy rating. Fortis shares closed at $33.51 on Tuesday.
• SunTrust Robinson Humphrey initiated coverage on Spotify Technology S.A. SPOT with a Buy rating. The price target for Spotify Technology is set to $200. Spotify Technology shares closed at $164.88 on Tuesday.
• Jefferies initiated coverage on Alcoa Corporation AA with a Buy rating. The price target for Alcoa is set to $65. Alcoa shares closed at $51.99 on Tuesday.
• Janney Capital initiated coverage on Summit Therapeutics plc SMMT with a Buy rating. The price target for Summit Therapeutics is set to $27. Summit Therapeutics shares closed at $13.18 on Tuesday.